304 related articles for article (PubMed ID: 33658601)
1. Hyperreflective foci in predicting the treatment outcomes of diabetic macular oedema after anti-vascular endothelial growth factor therapy.
Huang CH; Yang CH; Hsieh YT; Yang CM; Ho TC; Lai TT
Sci Rep; 2021 Mar; 11(1):5103. PubMed ID: 33658601
[TBL] [Abstract][Full Text] [Related]
2. Hyperreflective Foci in Diabetic Macular Edema with Subretinal Fluid: Association with Visual Outcomes after Anti-VEGF Treatment.
Tang L; Luo D; Qiu Q; Xu GT; Zhang J
Ophthalmic Res; 2023; 66(1):39-47. PubMed ID: 35697006
[TBL] [Abstract][Full Text] [Related]
3. One-Year Results of Using a Treat-and-Extend Regimen without a Loading Phase with Anti-VEGF Agents in Patients with Treatment-Naive Diabetic Macular Edema.
Schwarzer P; Ebneter A; Munk M; Wolf S; Zinkernagel MS
Ophthalmologica; 2019; 241(4):220-225. PubMed ID: 30654365
[TBL] [Abstract][Full Text] [Related]
4. The impact of ganglion cell layer cysts in diabetic macular oedema treated with anti-vascular endothelial growth factor.
Ceklic L; Huf W; Ebneter A; Wolf S; Zinkernagel MS; Munk MR
Acta Ophthalmol; 2019 Dec; 97(8):e1041-e1047. PubMed ID: 31099498
[TBL] [Abstract][Full Text] [Related]
5. IMPACT OF LONG-TERM INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR ON PREEXISTING MICROSTRUCTURAL ALTERATIONS IN DIABETIC MACULAR EDEMA.
Wirth MA; Wons J; Freiberg FJ; Becker MD; Michels S
Retina; 2018 Sep; 38(9):1824-1829. PubMed ID: 28767550
[TBL] [Abstract][Full Text] [Related]
6. Aflibercept for Diabetic Macular Edema in Eyes Previously Treated With Ranibizumab and/or Bevacizumab May Further Improve Macular Thickness.
Shah CP; Heier JS
Ophthalmic Surg Lasers Imaging Retina; 2016 Sep; 47(9):836-9. PubMed ID: 27631479
[TBL] [Abstract][Full Text] [Related]
7. Intravitreal Aflibercept for Patients With Diabetic Macular Edema Refractory to Bevacizumab or Ranibizumab: Analysis of Response to Aflibercept.
Chen YY; Chang PY; Wang JK
Asia Pac J Ophthalmol (Phila); 2017; 6(3):250-255. PubMed ID: 28436640
[TBL] [Abstract][Full Text] [Related]
8. Optical Coherence Tomography Angiography of DME and Its Association with Anti-VEGF Treatment Response.
Lee J; Moon BG; Cho AR; Yoon YH
Ophthalmology; 2016 Nov; 123(11):2368-2375. PubMed ID: 27613201
[TBL] [Abstract][Full Text] [Related]
9. CHANGES IN PLASMA VASCULAR ENDOTHELIAL GROWTH FACTOR LEVEL AFTER INTRAVITREAL INJECTION OF BEVACIZUMAB, AFLIBERCEPT, OR RANIBIZUMAB FOR DIABETIC MACULAR EDEMA.
Hirano T; Toriyama Y; Iesato Y; Imai A; Murata T
Retina; 2018 Sep; 38(9):1801-1808. PubMed ID: 29280940
[TBL] [Abstract][Full Text] [Related]
10. Optical Coherence Tomography Biomarkers in Predicting Treatment Outcomes of Diabetic Macular Edema after Ranibizumab Injections.
Chang YC; Huang YT; Hsu AY; Meng PP; Lin CJ; Lai CT; Hsia NY; Chen HS; Tien PT; Lin JM; Chen WL; Tsai YY
Medicina (Kaunas); 2023 Mar; 59(3):. PubMed ID: 36984630
[No Abstract] [Full Text] [Related]
11. Changes in choroidal thickness after anti-vascular endothelial growth factor treatment of diabetic macular edema, real-life data, 2-year results.
Savur F; Kaldırım H; Atalay K; Korkmaz Ş
Cutan Ocul Toxicol; 2021 Dec; 40(4):326-331. PubMed ID: 34275395
[TBL] [Abstract][Full Text] [Related]
12. Quantification of Fluid Resolution and Visual Acuity Gain in Patients With Diabetic Macular Edema Using Deep Learning: A Post Hoc Analysis of a Randomized Clinical Trial.
Roberts PK; Vogl WD; Gerendas BS; Glassman AR; Bogunovic H; Jampol LM; Schmidt-Erfurth UM
JAMA Ophthalmol; 2020 Sep; 138(9):945-953. PubMed ID: 32722799
[TBL] [Abstract][Full Text] [Related]
13. COMPARISON OF INTRAVITREAL DEXAMETHASONE IMPLANT AND AFLIBERCEPT IN PATIENTS WITH TREATMENT-NAIVE DIABETIC MACULAR EDEMA WITH SEROUS RETINAL DETACHMENT.
Ozsaygili C; Duru N
Retina; 2020 Jun; 40(6):1044-1052. PubMed ID: 30950970
[TBL] [Abstract][Full Text] [Related]
14. Short-Term Effects of Early Switching to Ranibizumab or Aflibercept in Diabetic Macular Edema Cases With Non-Response to Bevacizumab.
Ashraf M; Souka AA; ElKayal H
Ophthalmic Surg Lasers Imaging Retina; 2017 Mar; 48(3):230-236. PubMed ID: 28297035
[TBL] [Abstract][Full Text] [Related]
15. MEASUREMENTS OF RETINAL FLUID BY OPTICAL COHERENCE TOMOGRAPHY LEAKAGE IN DIABETIC MACULAR EDEMA: A Biomarker of Visual Acuity Response to Treatment.
Santos AR; Alves D; Santos T; Figueira J; Silva R; Cunha-Vaz JG
Retina; 2019 Jan; 39(1):52-60. PubMed ID: 29077605
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema Treatment: Analysis From the Diabetic Retinopathy Clinical Research Network Comparative Effectiveness Trial.
Ross EL; Hutton DW; Stein JD; Bressler NM; Jampol LM; Glassman AR;
JAMA Ophthalmol; 2016 Aug; 134(8):888-96. PubMed ID: 27280850
[TBL] [Abstract][Full Text] [Related]
17. Switching therapy from bevacizumab to aflibercept for the management of persistent diabetic macular edema.
Bahrami B; Hong T; Zhu M; Schlub TE; Chang A
Graefes Arch Clin Exp Ophthalmol; 2017 Jun; 255(6):1133-1140. PubMed ID: 28238195
[TBL] [Abstract][Full Text] [Related]
18. Similar real-world two-year visual acuity gains in treatment-naive patients with diabetic macular oedema treated with a loading dose of three initial monthly injections versus less intensive regimens of intravitreal anti-vascular endothelial growth factor.
Lindboe JB; Schmidt Laugesen C; Sørensen TL; Brynskov T
Acta Ophthalmol; 2021 Nov; 99(7):e1248-e1249. PubMed ID: 33956397
[No Abstract] [Full Text] [Related]
19. Microaneurysm density in residual oedema after anti-vascular endothelial growth factor therapy for diabetic macular oedema.
Yamada Y; Takamura Y; Morioka M; Gozawa M; Matsumura T; Inatani M
Acta Ophthalmol; 2021 Sep; 99(6):e876-e883. PubMed ID: 33326191
[TBL] [Abstract][Full Text] [Related]
20. Real-life experience of ranibizumab for diabetic macular edema in Taiwan.
Tsai MJ; Hsieh YT; Peng YJ
Int Ophthalmol; 2019 Jul; 39(7):1511-1522. PubMed ID: 29926364
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
